Effective October 10, 2024, Yan Qiong will join the management team of Eli Lilly (NYSE: LLY) China as the vice president of the diabetes products business unit. She will report directly to Huzur Devletsah, the president and general manager of Lilly China.
Yan Qiong brings nearly two decades of experience in the pharmaceutical industry, with previous roles at Novartis, AstraZeneca, and Menarini, where she served as chief executive officer. Before joining Eli Lilly, Yan held the position of senior vice president of cancer therapy at Novartis, leading the market launch of the cardiovascular drug Entresto (sacubitril/valsartan). In October 2022, she briefly transitioned to Menarini as CEO before returning to Novartis as the head of the field of cancer treatment. During her tenure, she contributed to the growth of Kisqali (ribociclib) and the introduction of significant radioligand therapies to China. Now, at Eli Lilly, Yan Qiong will concentrate on the growth of blockbuster drugs such as tirzepatide and metabolic series products in the Chinese market following her departure from Novartis in July 2024. – Flcube.com
